FDA
-
-
-
-
-
-
-
Appili Therapeutics raises C$177,500 in first tranche of private placement
-
-
-
-
-
-
-
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01
-
-
-
-
-
-
-
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
-
-
-
-
-
-
-
Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
-
-
-
-
-
-
-
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
-
-
-
-
-
-
-
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
-
-
-
-
-
-
-
Appili Therapeutics Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy
-
325,998 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

